Report cover image

Generics in Scandinavia

Publisher MarketLine
Published Dec 12, 2024
Length 40 Pages
SKU # MTLN19647874

Description

Generics in Scandinavia

Summary

Generics in Scandinavia industry profile provides top-line qualitative and quantitative summary information including: market size (value 2018-23, and forecast to 2028). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.

Key Highlights
  • A generic drug is defined as a copy of an ethical (prescription) drug formerly protected by patents that have now expired. Both unbranded generics and branded generics are included in our market scope. However, off-patent drugs that continue to be offered by the original manufacturer under the original name, and which form part of the 'generic-eligible' market, are not included. Market value is evaluated at ex-factory prices. Market volume refers to the proportion of the total ethical pharmaceutical market in a country or region that is made up of generic drugs. Thus, it is a measure of the market share held by generics, rather than a direct measure of the total market volume. Regional volumes are calculated as averages of countries that comprise the region where volume data exists.
  • The Scandinavian generics market recorded revenues of $4.2 billion in 2023, representing a compound annual growth rate (CAGR) of 4.2% between 2018 and 2023.
  • Market consumption volume increased with a CAGR of 2.5% between 2018 and 2023, to reach a total of 59.0% of total pharma volume in 2023.
  • According to GlobalData, in 2023, the Scandinavian generics market grew by 5.6% annually. The growth is attributed to the country’s mounting aging population, with a high prevalence of chronic diseases such as hypertension, diabetes, and cardiovascular conditions.
Scope
  • Save time carrying out entry-level research by identifying the size, growth, major segments, and leading players in the generics market in Scandinavia
  • Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the generics market in Scandinavia
  • Leading company profiles reveal details of key generics market players’ global operations and financial performance
  • Add weight to presentations and pitches by understanding the future growth prospects of the Scandinavia generics market with five year forecasts
Reasons to Buy
  • What was the size of the Scandinavia generics market by value in 2023?
  • What will be the size of the Scandinavia generics market in 2028?
  • What factors are affecting the strength of competition in the Scandinavia generics market?
  • How has the market performed over the last five years?
  • What are the main segments that make up Scandinavia's generics market?

Table of Contents

40 Pages
1 Executive Summary
1.1. Market value
1.2. Market value forecast
1.3. Market volume
1.4. Market volume forecast
1.5. Geography segmentation
1.6. Market rivalry
1.7. Competitive landscape
2 Market Overview
2.1. Market definition
2.2. Market analysis
3 Market Data
3.1. Market value
3.2. Market volume
4 Market Segmentation
4.1. Geography segmentation
5 Market Outlook
5.1. Market value forecast
5.2. Market volume forecast
6 Five Forces Analysis
6.1. Summary
6.2. Buyer power
6.3. Supplier power
6.4. New entrants
6.5. Threat of substitutes
6.6. Degree of rivalry
7 Competitive Landscape
7.1. Who are the leading players?
7.2. What are the strengths of the leading players?
7.3. Have there been any recent developments in the market?
8 Company Profiles
8.1. Bluefish Pharmaceuticals AB
8.2. Navamedic ASA
8.3. Teva Pharmaceutical Industries Ltd
8.4. AstraZeneca Plc
9 Macroeconomic Indicators
9.1. Country data
10 Appendix
10.1. Methodology
10.2. Industry associations
10.3. Related MarketLine research
10.4. About MarketLine
List of Tables
Table 1: Scandinavia generics market value: $ million, 2018-23
Table 2: Scandinavia generics market volume: % of total pharma volume, 2018-23
Table 3: Scandinavia generics market geography segmentation: $ million, 2023
Table 4: Scandinavia generics market value forecast: $ million, 2023-28
Table 5: Scandinavia generics market volume forecast: % of total pharma volume, 2023-28
Table 6: Bluefish Pharmaceuticals AB: key facts
Table 7: Bluefish Pharmaceuticals AB: Key Employees
Table 8: Navamedic ASA: key facts
Table 9: Navamedic ASA: Annual Financial Ratios
Table 10: Navamedic ASA: Key Employees
Table 11: Teva Pharmaceutical Industries Ltd: key facts
Table 12: Teva Pharmaceutical Industries Ltd: Annual Financial Ratios
Table 13: Teva Pharmaceutical Industries Ltd: Key Employees
Table 14: AstraZeneca Plc: key facts
Table 15: AstraZeneca Plc: Annual Financial Ratios
Table 16: AstraZeneca Plc: Key Employees
Table 17: Scandinavia exchange rate, 2018-23
List of Figures
Figure 1: Scandinavia generics market value: $ million, 2018-23
Figure 2: Scandinavia generics market volume: % of total pharma volume, 2018-23
Figure 3: Scandinavia generics market geography segmentation: % share, by value, 2023
Figure 4: Scandinavia generics market value forecast: $ million, 2023-28
Figure 5: Scandinavia generics market volume forecast: % of total pharma volume, 2023-28
Figure 6: Forces driving competition in the generics market in Scandinavia, 2023
Figure 7: Drivers of buyer power in the generics market in Scandinavia, 2023
Figure 8: Drivers of supplier power in the generics market in Scandinavia, 2023
Figure 9: Factors influencing the likelihood of new entrants in the generics market in Scandinavia, 2023
Figure 10: Factors influencing the threat of substitutes in the generics market in Scandinavia, 2023
Figure 11: Drivers of degree of rivalry in the generics market in Scandinavia, 2023
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.